ES8105388A1 - Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p. - Google Patents

Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p.

Info

Publication number
ES8105388A1
ES8105388A1 ES491832A ES491832A ES8105388A1 ES 8105388 A1 ES8105388 A1 ES 8105388A1 ES 491832 A ES491832 A ES 491832A ES 491832 A ES491832 A ES 491832A ES 8105388 A1 ES8105388 A1 ES 8105388A1
Authority
ES
Spain
Prior art keywords
production
transfer vector
vaccine
dna transfer
host transformed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES491832A
Other languages
English (en)
Other versions
ES491832A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26718684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8105388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of ES8105388A1 publication Critical patent/ES8105388A1/es
Publication of ES491832A0 publication Critical patent/ES491832A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

PROCEDIMIENTO PARA MANTENER, REPLICAR Y EXPRESAR UNA PORCION DEL GENOMA DE UN VIRUS NP. CONSTA DE LAS SIGUIENTES OPERACIONES: 1. AISLAR EL MATERIAL GENETICO, QUE COMPRENDE POR LO MENOS UNA PORCION DEL GENOMA DEL VIRUS NP O UN TRANSCRITO CADN DEL MISMO. 2. RECOMBINAR DICHO MATERIAL GENETICO CON UN VECTOR TRANSFERENTE DE ADN, FORMANDO UN VECTOR TRANSFERENTE RECOMBINANTE. 4. SELECCIONAR UNA CEPA DE CELULAS HUESPED CAPAD DE MANTENER, REPLICAR Y EXPRESAR EL VECTOR TRANSFERENTE RECOMBINANTE. 5. DESARROLLAR LA CELULA HUESPED SELECCIONADA EN CONDICIONES QUE FAVOREZCAN SU PROLIFERACION. EL VECTOR EMPLEADO ES PECO-63 Y EL HUESPED ES <<E. COLI>> HB-101. COMPRESION DE LA INUDCCION DE LAS ENFERMEDADES CRONICAS CAUSADAS TIPICAMENTE POR VIRUS NP.
ES491832A 1979-05-24 1980-05-23 Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p. Granted ES491832A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4190979A 1979-05-24 1979-05-24
US10726779A 1979-12-26 1979-12-26

Publications (2)

Publication Number Publication Date
ES8105388A1 true ES8105388A1 (es) 1981-05-16
ES491832A0 ES491832A0 (es) 1981-05-16

Family

ID=26718684

Family Applications (1)

Application Number Title Priority Date Filing Date
ES491832A Granted ES491832A0 (es) 1979-05-24 1980-05-23 Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p.

Country Status (11)

Country Link
US (1) US5436139A (es)
EP (1) EP0020251B1 (es)
JP (2) JPH0659221B2 (es)
CA (1) CA1341643C (es)
DE (2) DE3072205T2 (es)
DK (1) DK226680A (es)
ES (1) ES491832A0 (es)
GR (1) GR68524B (es)
IE (1) IE52036B1 (es)
PT (1) PT71296B (es)
YU (1) YU46343B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US6297355B1 (en) 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4249952A (en) * 1980-03-03 1981-02-10 Pennsylvania Engineering Corporation Method for producing cement clinker from cement kiln waste dust
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
DE3176404D1 (en) * 1980-04-22 1987-10-08 Pasteur Institut Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
IL63224A (en) * 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
EP0062574A3 (en) * 1981-03-31 1982-12-29 The Regents Of The University Of California Virus protein synthesis
EP0068719A3 (en) * 1981-06-16 1984-03-28 Takeda Chemical Industries, Ltd. Deoxyribonucleic acids, their production and use
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
EP0340806B1 (en) * 1981-08-04 1995-05-31 The Regents Of The University Of California Synthesis of human virus antigens by yeast
GR76274B (es) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
ZW18282A1 (en) 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
JPS58110600A (ja) * 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
US4460689A (en) * 1982-04-15 1984-07-17 Merck & Co., Inc. DNA Cloning vector TG1, derivatives, and processes of making
US4508826A (en) * 1982-04-15 1985-04-02 Merck & Co., Inc. Bacteriophage DNA cloning vector TG1 and microorganisms containing TG1
JPS5980615A (ja) * 1982-10-29 1984-05-10 Takeda Chem Ind Ltd Ｄｎａおよびその用途
US4703009A (en) * 1983-03-08 1987-10-27 Merck & Co., Inc. RDNA cloning vector pVE1, deletion and hybrid mutants and recombinant derivatives thereof products and processes
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector
US4859600A (en) * 1983-04-25 1989-08-22 Genentech, Inc. Recombinant procaryotic cell containing correctly processed human growth hormone
US4755465A (en) * 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US5158769A (en) * 1984-03-07 1992-10-27 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
EP0401941A3 (en) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Hepatitis b virus surface antigen and production thereof
DE3584866D1 (de) * 1984-09-12 1992-01-23 Chiron Corp Hybridpartikel-immunogene.
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
US7273695B1 (en) 1984-10-31 2007-09-25 Novartis Vaccines And Diagnostics, Inc. HIV immunoassays using synthetic envelope polypeptides
US7285271B1 (en) 1984-10-31 2007-10-23 Novartis Vaccines And Diagnostics, Inc. Antigenic composition comprising an HIV gag or env polypeptide
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
US7393949B1 (en) * 1987-12-24 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Human immunodeficiency virus (HIV) nucleotide sequences
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
AU1668788A (en) * 1987-05-26 1988-12-01 Wistar Institute, The Method of vaccination for hepatitis b virus
DE10299017I2 (de) * 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid.
EP0338620A1 (en) * 1988-04-18 1989-10-25 Merck & Co. Inc. Recovery of hepatitis B surface antigen
US4953930A (en) * 1989-03-15 1990-09-04 Ramtech, Inc. CPU socket supporting socket-to-socket optical communications
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US5651568A (en) * 1992-10-09 1997-07-29 Gainsborough Hardware Industries, Limited Privacy snib mechanism
US6759193B2 (en) * 1999-07-28 2004-07-06 The Government Of The Republic Of Singapore Detection of human hepatitis B virus surface antigen mutants by specific amplification and its application on gene chip

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
YU44186B (en) * 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes

Also Published As

Publication number Publication date
JPH02450A (ja) 1990-01-05
DE3072205D1 (de) 1993-02-25
DK226680A (da) 1980-11-25
GR68524B (es) 1982-01-11
PT71296B (en) 1981-09-21
CA1341643C (en) 2023-02-28
IE52036B1 (en) 1987-05-27
EP0020251A3 (en) 1981-05-20
YU46343B (sh) 1993-10-20
YU140380A (en) 1988-10-31
DE3072205T2 (de) 1993-08-05
JPS5663995A (en) 1981-05-30
JP2543751B2 (ja) 1996-10-16
EP0020251B1 (en) 1993-01-13
DE20251T1 (de) 1986-02-27
US5436139A (en) 1995-07-25
JPH0659221B2 (ja) 1994-08-10
PT71296A (en) 1980-06-01
EP0020251A2 (en) 1980-12-10
IE800991L (en) 1980-11-24
ES491832A0 (es) 1981-05-16

Similar Documents

Publication Publication Date Title
ES8105388A1 (es) Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p.
EP0151079A3 (en) Vaccine against epstein-barr virus
ES2002490A6 (es) Un metodo de preparar un virus recombinante
EP0500917A4 (en) Recombinant herpes simplex viruses vaccines and methods
NZ192465A (en) Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
DK577783A (da) Vektor for udtrykkelse af et dna-segment i gaer
ATE59409T1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
IL69423A0 (en) Recombinant plasmid inserted with hepatitis b virus gene,yeast transformed with said recombinant plasmid and production of hepatitis b virus surface antigen
ES8706208A1 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
MY102920A (en) Hepatitis b virus vaccine.
EP0105149A3 (en) Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
EP0019218A3 (en) Influenza virus vaccines, process for preparing them, process for propagating influenza viruses and cell culture inoculated with influenza virus
EP0068719A3 (en) Deoxyribonucleic acids, their production and use
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
FI885296A (fi) Rekombinant hiv-2 polypeptid.
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.
ES2165840T3 (es) Vacunas para la hepatitis a.
Bouges-Bocquet et al. In vitro genetic constructions devised to express given antigenic determinants at the surface of gram-negative bacteria.
Gerin et al. Recombinant DNA and synthetic peptide approaches to HBV vaccine development: Immunogenicity and protective efficacy in chimpanzees.
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ
Tikhonenko Prospects and achievements in the development of genetically engineered antiviral vaccines.
Smirnov et al. Synthesis and expression of the DNA fragment coding for antigenic determinant of the protein of hepatitis virus B surface antigen.
Tikchonenko Perspectives and achivements in the construction of gene engineering antiviral vaccines.
Leung et al. A direct cloning-expression system for neutralization antigens of herpes simplex viruses.